US Edition
News from european-biotechnology.com
If you want to know if European-biotechnology.com is credible or reliable, look no further. We rank European-biotechnology.com as Unknown factuality. Find out more about our methodology here.
Information about European-biotechnology.com
Where is European-biotechnology.com located?European-biotechnology.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top European-biotechnology.com News
PharmaAvidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver. The post Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition appeared first on MedCity News.See the Story
Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
Coverage: 5 sources
London, England · LondonLONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B financing round. The round was co-led by a new lead, Schroders Capital, as well as existing investors Atlas Venture and Forbion. Other new investors included Amgen Ventures, Athos Capit…See the Story
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
100% Center coverage: 2 sources
